| Title: |
mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients |
| Authors: |
Kwon, Jennie H; Tenforde, Mark W; Gaglani, Manjusha; Talbot, H Keipp; Ginde, Adit A; McNeal, Tresa; Ghamande, Shekhar; Douin, David J; Casey, Jonathan D; Mohr, Nicholas M; Zepeski, Anne; Shapiro, Nathan I; Gibbs, Kevin W; Files, D Clark; Hager, David N; Shehu, Arber; Prekker, Matthew E; Caspers, Sean D; Exline, Matthew C; Botros, Mena; Gong, Michelle N; Li, Alex; Mohamed, Amira; Johnson, Nicholas J; Srinivasan, Vasisht; Steingrub, Jay S; Peltan, Ithan D; Brown, Samuel M; Martin, Emily T; Khan, Akram; Hough, Catherine L; Busse, Laurence W; Duggal, Abhijit; Wilson, Jennifer G; Perez, Cynthia; Chang, Steven Y; Mallow, Christopher; Rovinski, Randal; Babcock, Hilary M; Lauring, Adam S; Felley, Laura; Halasa, Natasha; Chappell, James D; Grijalva, Carlos G; Rice, Todd W; Womack, Kelsey N; Lindsell, Christopher J; Hart, Kimberly W; Baughman, Adrienne; Olson, Samantha M |
| Contributors: |
Centers for Disease Control and Prevention; Clinical and Translational Science Award |
| Source: |
The Journal of Infectious Diseases ; volume 226, issue 5, page 797-807 ; ISSN 0022-1899 1537-6613 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2022 |
| Description: |
Background The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients. Methods We conducted a 21-site case-control analysis of 10 425 adults hospitalized in March to December 2021. Cases were hospitalized with COVID-19; controls were hospitalized for an alternative diagnosis (severe acute respiratory syndrome coronavirus 2-negative). Participants were classified as follows: SOT recipient (n = 440), other immunocompromising condition (n = 1684), or immunocompetent (n = 8301). The VE against COVID-19-associated hospitalization was calculated as 1-adjusted odds ratio of prior vaccination among cases compared with controls. Results Among SOT recipients, VE was 29% (95% confidence interval [CI], −19% to 58%) for 2 doses and 77% (95% CI, 48% to 90%) for 3 doses. Among patients with other immunocompromising conditions, VE was 72% (95% CI, 64% to 79%) for 2 doses and 92% (95% CI, 85% to 95%) for 3 doses. Among immunocompetent patients, VE was 88% (95% CI, 87% to 90%) for 2 doses and 96% (95% CI, 83% to 99%) for 3 doses. Conclusions Effectiveness of COVID-19 mRNA vaccines was lower for SOT recipients than immunocompetent adults and those with other immunocompromising conditions. Among SOT recipients, vaccination with 3 doses of an mRNA vaccine led to substantially greater protection than 2 doses. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/infdis/jiac118 |
| DOI: |
10.1093/infdis/jiac118/43540578/jiac118.pdf |
| Availability: |
https://doi.org/10.1093/infdis/jiac118; https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiac118/43540578/jiac118.pdf; https://academic.oup.com/jid/article-pdf/226/5/797/45820283/jiac118.pdf |
| Rights: |
https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model |
| Accession Number: |
edsbas.377D2F17 |
| Database: |
BASE |